Ulf Jungnelius

Ulf Jungnelius

MD / Chief Executive Officer

Ulf has been a director of Isofol since 2010 and has been its clinical and regulatory expert. He has a long and successful experience within oncology research and development including leading positions in the United States in Celgene, Takeda, Pfizer and Eli Lilly. Ulf has had key roles in the clinical development and market approval of drugs such as Alimta® (pemetrexed), Revlimid® (lenalidomide), Vidaza® (azacitidine) and Abraxane (nab + paclitaxel). In addition, Ulf has participated in several major Due Diligence processes that have resulted in multi-billion acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.

Position: Chief Executive Officer

Year of birth: 1951

Holdings: 233 336 shares*, 250 000 warrants**

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of December 31, 2021.
** Isofol Medical AB (publ) warrent program 2018 series 2018/2022 and 2018/2023. For more information and terms read more under Corporate Governance.